No Benefit from Chest Wall Irradiation in Intermediate-Risk Breast ...
Dec 15, 2024 · Study shows chest wall irradiation post-mastectomy offers no survival benefit for most intermediate-risk breast cancer patients.
ACG Updates Guidelines For Eosinophilic Oesophagitis Management
Jan 9, 2025 · The latest clinical guidelines from the American College of Gastroenterology aim to improve the diagnosis and treatment of eosinophilic oesophagitis. Read now.
Update on Low-Molecular Weight Hyaluronic Acid in …
Nov 7, 2024 · Key Points 1. This paper provides a comprehensive review of low molecular weight hyaluronic acid (LMW-HA) and its emerging role in dermatology. While hyaluronic acid’s utility is well-established across various medical fields, LMW-HA’s unique properties, such as its antimicrobial effects and ability to penetrate the skin more effectively than its high molecular weight counterpart, present ...
Stem-Cell Therapy Success in China Marks Milestone in Type 1 …
Nov 9, 2024 · 25-year-old woman with Type 1 diabetes in China has successfully undergone a stem-cell therapy that enabled her to produce her own insulin, reducing her reliance on injections.
The Advances in Treatment Options for Conditions Causing Hair Loss
Nov 7, 2024 · DRUGS Oral and topical JAK inhibitors have emerged as promising treatments for autoimmune-related hair loss, particularly alopecia areata. 3 JAK inhibitors function through inhibition of enzymes in the JAK/signal transducer and activator of transcription (STAT) signalling pathway, regulating immune system activity. Currently, three JAK inhibitors have been approved by the FDA for the treatment ...
Why EGFR Exon 21 L858R Mutations Should Be Treated Differently
BACKGROUND EGFR gene mutations have been reported in 15–60% of non-small cell lung cancers (NSCLCs) with an important difference in prevalence between Eastern and Western populations. 1,2 The most common EGFR -activating mutations in NSCLC include in-frame deletions in exon 19 and a substitution in exon 21 (L858R) which account for 47% and 41%, respectively, of observed EGFR mutations in ...
In this poster presentation, Carlo Antozzi outlined top-line results from the 24-week, double-blind, placebo-controlled, randomised Vivacity-MG3 Phase III study (NCT04951622).1 Nipocalimab, he explained, demonstrated efficacy and safety in a broad antibody-positive population, suggesting it could provide the first FcRn treatment option with a predictable dosing schedule in …
Multidisciplinary Team Approach in Cancer Care: A Review of The …
Nov 18, 2021 · Disclosure: Scott has declared no conflicts of interest. Support: The publication of this article was funded by a medical educational grant from AstraZeneca with the purpose of enhancing the fundamental understanding of oncology specialists of the value of a multidisciplinary team (MDT) approach in the management of patients with cancer. Received: 05.10.21 Accepted: 28.10.21 Citation:
Radiation Therapy Shows Promise for Liver Cancer Survival
Dec 29, 2024 · A phase 3 clinical trial suggests that stereotactic body radiation therapy prior to systemic treatment may improve survival outcomes for patients with liver cancer. Read more!
EMJ | Elevating the quality of healthcare globally
Our independent, open-access journals are dedicated to delivering insights into ground-breaking changes and advancements in medicine